Share-based Payment Arrangement, Expense of Kalaris Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kalaris Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • Kalaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $638,000, a 144% increase year-over-year.
  • Kalaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $27,335,000, a 158% increase year-over-year.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $26,347,000, a 35% decline from 2023.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $40,779,000, a 1.3% decline from 2022.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $41,315,000, a 6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Kalaris Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $27,335,000 $638,000 +$376,000 +144% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $26,959,000 $591,000 +$269,000 +84% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $26,690,000 $374,000 +$343,000 +1106% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $26,347,000 $25,732,000 +$15,738,000 +157% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 $10,609,000 $262,000 -$10,206,000 -97% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $20,815,000 $322,000 -$9,966,000 -97% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $30,781,000 $31,000 -$9,998,000 -100% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $40,779,000 $9,994,000 +$952,000 +11% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $39,827,000 $10,468,000 -$387,000 -3.6% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $40,214,000 $10,288,000 -$663,000 -6.1% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $40,877,000 $10,029,000 -$438,000 -4.2% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $41,315,000 $9,042,000 -$6,818,000 -43% 01 Oct 2022 31 Dec 2022 10-K 15 Mar 2024 2023 FY
Q3 2022 $48,133,000 $10,855,000 +$569,000 +5.5% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $47,564,000 $10,951,000 +$1,225,000 +13% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $46,339,000 $10,467,000 +$2,364,000 +29% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $43,975,000 $15,860,000 +$11,429,000 +258% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2023 2022 FY
Q3 2021 $32,546,000 $10,286,000 +$6,426,000 +166% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $26,120,000 $9,726,000 +$9,234,000 +1877% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $16,886,000 $8,103,000 +$7,457,000 +1154% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $9,429,000 $4,431,000 01 Oct 2020 31 Dec 2020 10-K 10 Feb 2022 2021 FY
Q3 2020 $3,860,000 +$3,264,000 +548% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $492,000 -$949,000 -66% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $646,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q3 2019 $596,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $1,441,000 01 Apr 2019 30 Jun 2019 10-Q 02 Sep 2020 2020 Q2

Kalaris Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $26,347,000 -$14,432,000 -35% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $40,779,000 -$536,000 -1.3% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $41,315,000 -$2,660,000 -6% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024 2023 FY
2021 $43,975,000 +$34,546,000 +366% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2023 2022 FY
2020 $9,429,000 +$6,539,000 +226% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2022 2021 FY
2019 $2,890,000 01 Jan 2019 31 Dec 2019 10-K 12 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.